Parasite | Eso | Sto | Cancer | ESD
[EsoTODAY 036 - Esophageal neuroendocrine carcinoma. ½Äµµ ½Å°æ³»ºÐºñ¾Ï]
³»³âµµ¿¡ ÀúÈñ ÆÀ¿¡¼ fellow¸¦ ÇÏ½Ç ¼±»ý´Ôµé°ú ÇÔ²² ³»½Ã°æ description exercise ¹®Á¦¸¦ Ç®°í ÀÖ½À´Ï´Ù. ¸»ÇÏÀÚ¸é ³»½Ã°æ ¼±ÇàÇнÀ´Ï´Ù. ±× Áß ÇÑ Áõ·Ê¸¦ ¼Ò°³ÇÕ´Ï´Ù.
¼Ò°ß: »óºÎ½Äµµ 5½Ã ¹æÇâ¿¡ 1cm Å©±âÀÇ Á¤»ó Á¡¸·À¸·Î µ¤ÀÎ molar tooth shapeÀÇ elevated lesionÀÌ ÀÖ½À´Ï´Ù. EUS¿¡¼ 2nd lay¿¡¼ originÇÏ´Â mixed hyperechoic lesionÀÔ´Ï´Ù.
Áø´Ü: Esophageal SET (granular cell tumor, more likely)
[ÀÌÁØÇà comment]
½Äµµ SET (SMT¶ó°í ºÒ·¯µµ ÁÁ½À´Ï´Ù)ÀÔ´Ï´Ù. ¾î±Ý´Ï ¸ð¾çÀ̹ǷΠ´ëºÎºÐ granular cell tumor¶ó°í ´äÇÏ´Â ¹®Á¦ÀÔ´Ï´Ù. Á¤´äÀº ¾Æ´ÏÁö¸¸ ³»½Ã°æÀ¸·Î´Â ±×·¸°Ô¹Û¿¡ ÇÒ ¼ö ¾ø½À´Ï´Ù. Á¶Á÷°Ë»ç°¡ ²À ÇÊ¿äÇÑ Áõ·ÊÀÔ´Ï´Ù.
Á¤´äÀº large cell neuroendocrine carcinoma¿´½À´Ï´Ù. ³»½Ã°æ°ú EUS ¼Ò°ß¸¸À¸·Î Á¤È®ÇÑ Áø´ÜÀ» ¸ÂÃâ ¼ö ¾ø´Â °ÍÀº ´ç¿¬ÇÑ ÀÏÀÔ´Ï´Ù. Á¶Á÷°Ë»çµµ neuroendocrine tumor ÀÎ °Í±îÁö¸¸ ¾Ë·ÁÁÖ°í, neuroendocrine carcinomaÀÎ °ÍÀº ESD ÈÄ ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ÀϹÝÀûÀÎ granular cell tumor¿Í ´Ù¸¥ Á¡À» ¤¾îº»´Ù¸é... »öÁ¶ Á¤µµ¸¦ ¸»ÇÒ ¼ö ÀÖ°Ú½À´Ï´Ù. Granular cell tumor´Â Á» ´õ ³ë¶þ°Ô ºñÃÄ º¸À̴ϱî¿ä. ÇÑ ¼±»ý´Ô²²¼ neuroendocrine carcinoma¸¦ »ý°¢Çϼ̽À´Ï´Ù. Á¤´äÀ» Á¦½ÃÇÑ Á¡Àº ÁÁ±â´Â ÇÑÁö¸¸, ÀϹÝÀûÀÎ °ÍÀ» ¸ÕÀú ¶°¿Ã¸®´Â °ÍÀÌ ÀÚ¿¬½º·¯¿ï °Í °°½À´Ï´Ù.
Á¶Á÷°Ë»ç¿¡¼ neuroendocrine tumor·Î ³ª¿Í ESD¸¦ ÇÏ¿© large cell neuroendocrine carcinoma with submucosal and lymphatic invasionÀ¸·Î ³ª¿Í ¼ö¼úÀ» ±ÇÇß½À´Ï´Ù.
1. Name of Procedure: ESD
2. Site of Tumor: Esophagus
3. Diagnosis: Large cell neuroendocrine carcinoma
4. WHO classification(2010): Neuroendocrine carcinoma
5. Multiplicity: Single
6. Size: 0.9x0.8 cm
7. Extent: Mucosa and submucosa
8. Grading: Mitotic Count: >20/10 HPF. Ki-67 labeling index: G3>20%
9. Immunohistochemical Stains - Synaptophysin : Positive, Chromogranin A: Positive, CD56: Positive, Ki-67: Positive (60%), PHH-3: Positive (198/10 HPFs)
10. Lymphovascular invasion: Present
11. Perineural invasion: Not identified
12. Resection Margins: Involved by tumor with cautery artifactsESD º´¸®. Á¡¸·ÃþÀº ºñ±³Àû intact Çѵ¥ ±× ¾Æ·¡·Î homogenousÇÑ ½Å°æ³»ºÐºñ¼¼Æ÷°¡ ³Ð°Ô º¸ÀÓ.
ESD º´¸®. ¶Ñ·ÇÇÑ endolymphatic emboli°¡ °üÂûµÇ¾úÀ½.
¼ö¼ú °á°ú¿¡¼´Â ¾Æ·¡¿Í °°ÀÌ lymph node metastasis°¡ ÀÖ¾ú½À´Ï´Ù. ¿ª½Ã ¼ö¼úÀ» º¸³»±â¸¦ Àß Çß´Ù°í »ý°¢ÇÏ¿´½À´Ï´Ù. »óºÎ½Äµµ º´¼ÒÀÎÁö¶ó ȯÀÚ²²¼ ¼ö¼ú ÈÄ °í»ýÀ» ¸¹ÀÌ Çϼ̽À´Ï´Ù.
Esophagus and upper stomach, Ivor Lewis operation:
; "LRLN", 0/2; "L9", 0/1; "L10", 0/1; "RD", 0/1; "5", 0/1; "7", 0/2; "8u", 0/1)
Status post endoscopic submucosal dissection (D13-7695)
No residual tumor
1) tumor size: cannot be determined (no residual tumor)
2) depth of invasion: cannot be determined (no residual tumor)
3) endolymphatic tumor emboli: not identified
4) perineural invasion: not identified
5) resection margins: free from carcinoma, safety margin: proximal, 1.5 cm ; distal, 18 cm ;
6) metastasis to 1 out of 25 regional lymph nodes (1/25: "LC omentum", 0/0; "G1", 0/3; "G2", 0/3; "G3", 0/8; "RRLN (right recurrent laryngeal nerve)", 1/2
7) treatment effect: not applicable
Dysphagia and chest pain
Composite squamous and pooly differentiated neuroendocrine carcinoma
1) EsoTODAY - Esophageal diseases
2) SmallTODAY - Small bowel diseases
3) ColonTODAY - Colorectal diseases
4) Dr. Sinn's LiverTODAY - Liver diseases
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (2017-12-24)